The following presentations were given at the Plenary Session of the Spring 2008 Group Meeting in Atlanta, Georgia, "Southwest Oncology Group Showcase 2008." They are in Windows Media Video format, and should automatically start in the default player for .wmv files on your computer when you click the icon at the right of the presentation title.

Saturday, May 3, 2008
Chair's Commentary and Presentation Laurence H. Baker Chair, Southwest Oncology Group Professor, Internal Medicine & Pharmacology, University of Michigan Ann Arbor, Michigan
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from SWOG-9346 and S9916 Maha H.A. Hussain, M.D. Professor of Internal Medicine and Urology, University of Michigan, Ann Arbor
	Discussant Nicholas Vogelzang, M.D. Director Nevada Cancer Institute, Las Vegas
A randomized phase III trial of cisplatin and irinotecan versus cisplatin and etoposide in 671 patients with extensive stage small cell lung cancer, SWOG trial S0124 Ronald B. Natale, M.D. Director, National Lung Cancer Research Program and Senior Research Advisor for the Solid Tumor Program for Aptium Oncology, Los Angeles, California
	Discussant Christine Ambrosone, Ph.D. Professor of Oncology, Chair and Associate Professor, Department of Social and Preventive Medicine at University at Buffalo, Director of Epidemiology Roswell Park Cancer Institute, Buffalo, New York
SWOG-8814: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-negative, ER-positive breast cancer (SWOG-8814, TBCI-0100) Kathy S. Albain, M.D. Professor of Medicine, Hematology and Oncology, Loyola University, Maywood, Illinois
	Discussant Eric Winer, M.D. Associate Professor, Department of Medicine, Harvard Medical School, Director, Breast Oncology Center, Dana Farber Cancer Institute, Boston, Massachusetts
Randomized Phase III Clinical Trial Designs for Targeted Agents Antje Hoering, Ph.D. Senior Biostatistician, Cancer Research and Biostatistics (CRAB), Affiliate Investigator, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Affiliate Assistant Professor, Department of Biostatistics, University of Washington, Seattle
	Discussant Richard I. Fisher, M.D. Vice President for Clinical Services, University of Rochester Medical Center, Director, James P. Wilmot Cancer Center, Director, Hematology/Oncology Division, Samuel E. Durand Professor of Medicine, University of Rochester, Rochester, New York
Superiority of lenalidomide plus high-dose dexamethasone compared to HD alone as treatment of newly-diagnosed multiple myeloma: results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 Jeffrey A. Zonder, M.D. Assistant Professor of Medicine and Hematology-Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan